Adult patients with standard-risk ALL who undergo allogeneic transplant in the first complete remission have a significant survival advantage over conventional therapy; however, the transplant-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk," he said, adding that there is no evidence that a single autologous transplant can replace standard consolidation/maintenance therapy in any risk group.
In the study, designed to examine duration of response after high-dose VAD therapy, patients received two autologous transplants (with melphalan doses of 140mg/m2 and 200mg/m2, respectively); those without progressive disease after two months were randomized to receive no maintenance (arm A), pamidronate maintenance (arm B), or pamidronate maintenance with thalidomide (arm C).
Although allogeneic stem cell transplantation is the only potentially curative option at present for Hodgkin lymphoma patients who relapse following an autologous transplant, only 20 to 25 percent of these patients achieve long-term benefit," said Owen A.
Research has shown that allogeneic stem cell transplantation can be a curative procedure for certain groups of patients with multiple myeloma; however, it can be associated with increased morbidity and mortality over autologous transplant.
Significant differences among the groups were found, however, with regard to overall survival, which stood at 52% for the chemotherapy patients, 46% for the allogeneic group, and 43% for the autologous transplant patients.
Mozobil has shown the ability to quickly and predictably prepare a patient for a transplant, providing a strong clinical and economic argument in favor of its use in all autologous transplant procedures.
This is the first time we have evidence that umbilical cord blood (UCB) can be used in an autologous transplant to treat childhood leukemia," states Jack Goldberg, MD, CorCell Medical Director and Chief of Hematology Oncology at the University of Pennsylvania Health System, PennPresbyterian.
Up to 10 percent of bone marrow donors fail to mobilize sufficient numbers of stem cells, which impedes autologous transplants and significantly delays transplant recovery time," said Hartmut Geiger, Ph.